On Thursday, Shares of SunEdison, Inc. (NYSE:SUNE), gained 1.13% to $11.63, after the Northern District of California dismissed SunPower’s (SPWR - Get Report) lawsuit against the solar energy company, with leave to amend.
SunPower filed the lawsuit against certain SunEdison employees who formerly worked for the former energy company in June. The lawsuit claimed the former employees violated the Computer Fraud and Abuse Act (CFAA) by breaching SunPower’s computer use policies and misappropriating its information.
The court granted SunEdison’s motion to dismiss the claims under the CFAA, ruling that SunPower “failed to adequately plead a CFAA claim.”
In a separate declaration, SunEdison declared Wednesday that it is supplying advanced battery systems in a project to build nine net-zero energy homes in Fontana, CA. The project is led by the Electric Power Research Institute with the aim of evaluating how net-zero energy homes that generate and store their own energy impact electricity grids.
SunEdison, Inc. develops, manufactures, and sells silicon wafers to the semiconductor industry. The company operates through three segments: Solar Energy, TerraForm Power, and Semiconductor Materials. The Solar Energy segment provides solar energy services that integrate the design, installation, financing, monitoring, operations, and maintenance portions of the downstream solar market. It also manufactures polysilicon, silicon wafers, and solar modules.
Shares of Nokia Corporation (NYSE:NOK), inclined 0.30% to $6.74, during its last trading session.
Nokia Corporation declared that it has obtained clearance from the Committee on Foreign Investment in the United States (“CFIUS”) for its projected acquisition of Alcatel-Lucent. With the conclusion of the CFIUS process and the formerly declared antitrust clearance by the U.S. Department of Justice, the companies have received the required regulatory approvals for the projected transaction in the United States.
Both companies will continue to work closely with the few remaining antitrust authorities in the relevant jurisdictions to conclude their regulatory reviews as quickly as possible. The projected transaction remains subject to approval by Nokia shareholders, Nokia holding over 50.00% of the share capital of Alcatel-Lucent on a fully diluted basis upon completion of the public exchange offer, receipt of the remaining regulatory approvals and other customary conditions. The projected transaction is predictable to close in the first half of 2016.
Nokia Corporation, together with its auxiliaries, provides network infrastructure and related services in Finland, the United States, Japan, China, India, the Russian Federation, Germany, Taiwan, Indonesia, Italy, and internationally. The company operates through four segments: Mobile Broadband, Global Services, HERE, and Nokia Technologies.
Finally, Horizon Pharma plc (NASDAQ:HZNP), ended its last trade with 7.78% surge, and closed at $31.16.
Depomed, Inc. (DEPO) declared that its Board of Directors, after careful consideration and in consultation with its financial and legal advisors, has unanimously determined to recommend that shareholders reject Horizon Pharma plc’s (HZNP) unsolicited exchange offer to acquire all of the outstanding shares of Depomed at an exchange ratio of 0.95 of an ordinary Horizon share for each share of Depomed.
“Our Board of Directors unanimously concluded that Horizon’s unsolicited exchange offer significantly undervalues Depomed, is inadequate and is not in the best interests of Depomed and its shareholders,” said Jim Schoeneck, President and CEO of Depomed and Peter D. Staple, Depomed’s Chairman of the Board. “We remain very confident in the growth prospects of NUCYNTA and our strong portfolio of products for pain and neurology related disorders. We continue to believe that Horizon’s exchange offer is opportunistic and would transfer the future value of Depomed to Horizon at a price we believe does not represent the value of Depomed’s assets, business and prospects.”
In reaching its recommendation that shareholders reject Horizon’s exchange offer, the Depomed Board of Directors considered numerous factors in consultation with Depomed’s administration and advisors.
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
